Explore
Validate
Learn
Immunohistochemistry
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Other assay [4]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-11538 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- GnRHR Monoclonal Antibody (GNRH03)
- Antibody type
- Monoclonal
- Antigen
- Synthetic peptide
- Description
- MA5-11538 targets GnRH Receptor in FACS, IF, and IHC (P) applications and shows reactivity with Human samples. The MA5-11538 immunogen is a synthetic peptide aa 1-29 (MAN-SASPEQNQNHCSAINNSIPLMQGNLPY) from the N-terminal of human GnRH receptor.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- GNRH03
- Vial size
- 500 µL
- Concentration
- 0.2 mg/mL
- Storage
- 4° C
Submitted references GnRH antagonist treatment of malignant adrenocortical tumors.
In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth.
Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma.
Gonadotropin-releasing hormone-II increases membrane type I metalloproteinase production via beta-catenin signaling in ovarian cancer cells.
Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro.
GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors.
Presence of immunoreactive gonadotropin releasing hormone (GnRH) and its receptor (GnRHR) in rat ovary during pregnancy.
Expression and localization of gonadotropin-releasing hormone receptor in the rat oviduct during pregnancy.
Doroszko M, Chrusciel M, Stelmaszewska J, Slezak T, Anisimowicz S, Plöckinger U, Quinkler M, Bonomi M, Wolczynski S, Huhtaniemi I, Toppari J, Rahman NA
Endocrine-related cancer 2019 Jan 1;26(1):103-117
Endocrine-related cancer 2019 Jan 1;26(1):103-117
In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth.
Sakai M, Martinez-Arguelles DB, Patterson NH, Chaurand P, Papadopoulos V
PloS one 2015;10(3):e0120670
PloS one 2015;10(3):e0120670
Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma.
Li Q, Coulson H, Klaassen Z, Sharma S, Ramalingam P, Moses KA, Terris MK
Prostate cancer and prostatic diseases 2013 Dec;16(4):387-90
Prostate cancer and prostatic diseases 2013 Dec;16(4):387-90
Gonadotropin-releasing hormone-II increases membrane type I metalloproteinase production via beta-catenin signaling in ovarian cancer cells.
Ling Poon S, Lau MT, Hammond GL, Leung PC
Endocrinology 2011 Mar;152(3):764-72
Endocrinology 2011 Mar;152(3):764-72
Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro.
Klemmt PA, Liu F, Carver JG, Jones C, Brosi D, Adamson J, Mardon HJ, McVeigh E
Human reproduction (Oxford, England) 2009 Sep;24(9):2187-92
Human reproduction (Oxford, England) 2009 Sep;24(9):2187-92
GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors.
Angelucci C, Lama G, Iacopino F, Ferracuti S, Bono AV, Millar RP, Sica G
Endocrine 2009 Aug;36(1):87-97
Endocrine 2009 Aug;36(1):87-97
Presence of immunoreactive gonadotropin releasing hormone (GnRH) and its receptor (GnRHR) in rat ovary during pregnancy.
Sengupta A, Chakrabarti N, Sridaran R
Molecular reproduction and development 2008 Jun;75(6):1031-44
Molecular reproduction and development 2008 Jun;75(6):1031-44
Expression and localization of gonadotropin-releasing hormone receptor in the rat oviduct during pregnancy.
Sengupta A, Sridaran R
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2008 Jan;56(1):25-31
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2008 Jan;56(1):25-31
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human pituitary stained with GnRH-Receptor antibody using peroxidase-conjugate and AEC chromogen. Note cytoplasmic staining of anterior pituitary cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 GNRHR knockdown in H295R adrenocortical carcinoma cells. Western blot analysis of GNRHR expression in WT (H295R), transfected with non-targeting (siControl) or GNRHR-targeting (siGNRHR) siRNA H295R adrenocortical carcinoma cells (A). Densitometric analysis of the GNRHR protein levels in H295R, siControl and siGNRHR cells ( n = 3) (B). The effect of CTX treatment on proliferation ( n = 12) (C) and caspase 3/7 activation ( n = 9) (D) in siControl and siGNRHR cells (mean +- s.e.m. ; * P
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 3 GnRHR levels in BPH-1 and LNCaP cells. Representative immunoblots of BPH-1 and LNCaP cell extracts. Each lane represents an independent cell passage (n = 3).
